DURECT Corporation (DRRX) Receives Daily Media Sentiment Rating of 0.17
News articles about DURECT Corporation (NASDAQ:DRRX) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. DURECT Corporation earned a news impact score of 0.17 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 46.2643458837695 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- DURECT Corporation (NASDAQ:DRRX) Gives Positive Technical Signals Today – StockNewsGazette (stocknewsgazette.com)
- DURECT Corp (DRRX) Showing Bullish Money Flow – Sheridan Daily (sheridandaily.com)
- DRRX: A $293 Million Deal with Sandoz for POSIMIR® in the United States (finance.yahoo.com)
- DURECT Corporation Announces Second Quarter 2017 Financial Results and Provides Corporate Update – GuruFocus.com (gurufocus.com)
- Edited Transcript of DRRX earnings conference call or presentation 8-Aug-17 8:30pm GMT (finance.yahoo.com)
Shares of DURECT Corporation (NASDAQ DRRX) traded up 4.43% during mid-day trading on Friday, hitting $1.65. The stock had a trading volume of 781,052 shares. The firm has a 50 day moving average price of $1.68 and a 200 day moving average price of $1.21. The firm’s market cap is $242.55 million. DURECT Corporation has a 52-week low of $0.74 and a 52-week high of $1.95.
DURECT Corporation (NASDAQ:DRRX) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.02. DURECT Corporation had a negative net margin of 221.01% and a negative return on equity of 629.35%. The business had revenue of $4.32 million during the quarter, compared to analysts’ expectations of $5.17 million. Equities analysts predict that DURECT Corporation will post ($0.21) EPS for the current year.
DRRX has been the topic of several research analyst reports. Stifel Nicolaus upgraded DURECT Corporation from a “hold” rating to a “buy” rating and boosted their price target for the company from $1.25 to $3.00 in a research note on Wednesday, July 12th. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of DURECT Corporation in a research note on Sunday, June 25th.
COPYRIGHT VIOLATION WARNING: This article was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://theolympiareport.com/2017/08/12/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-durect-corporation-drrx-share-price-updated.html.
DURECT Corporation Company Profile
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.